Market Research Logo

Fungal Foot Infections Drug Development Pipeline Review, 2018

Fungal Foot Infections Drug Development Pipeline Review, 2018

Summary


Onychomycosis and athlete’s foot are non-life threatening fungal infections that most commonly affect the toenails and the feet respectively. Athlete’s foot affects 15% of the population globally, with males being more commonly affected than females. Onychomycosis affects roughly 10% of the global adult population.

There is considerable overlap in both the development of pipeline products and existing marketed products between the two indications, which reflects similarities in the underlying pathophysiology.

There are a total of 25 products in development across these indications, by 24 companies.

This report “Fungal Foot Infections Drug Development Pipeline Review, 2018” provides an overview of the onychomycosis (Tinea unguium) and athlete’s foot (Tinea pedis) pipeline landscapes. The report provides comprehensive information on the therapeutics under development and key players active in these two indications, and features dormant and discontinued projects.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared with pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Fungal Foot Infections Report Coverage
    • Onychomycosis (Tinea Unguium) –Overview
    • Tinea pedis (Athlete Foot) –Overview
  • Therapeutics Development
    • Onychomycosis (Tinea Unguium)
      • Pipeline Overview
        • Table Figure 1: Number of Products under Development for Onychomycosis (Tinea Unguium)
        • Table Number of Products under Development for Onychomycosis (Tinea Unguium)
      • Pipeline by Companies
        • Table Figure 2: Number of Products under Development by Companies, Onychomycosis (Tinea Unguium)
        • Table Number of Products under Development by Companies, Onychomycosis (Tinea Unguium)
      • Products under Development by Companies
        • Table Products under Development by Companies, Onychomycosis (Tinea Unguium)
    • Tinea pedis (Athlete Foot)
      • Pipeline Overview
        • Table Figure 3: Number of Products under Development for Tinea pedis (Athlete Foot)
        • Table Number of Products under Development for Tinea pedis (Athlete Foot)
      • Pipeline by Companies
        • Table Figure 4: Number of Products under Development by Companies, Tinea pedis (Athlete Foot)
        • Table Number of Products under Development by Companies, Tinea pedis (Athlete Foot)
      • Products under Development by Companies
        • Table Products under Development by Companies, Tinea pedis (Athlete Foot)
  • Therapeutics Assessment
    • Onychomycosis (Tinea Unguium)
      • Assessment by Target
        • Table Figure 5: Number of Products by Targets, Onychomycosis (Tinea Unguium)
        • Table Figure 6: Number of Products by Stage and Targets, Onychomycosis (Tinea Unguium)
        • Table Number of Products by Stage and Target, Onychomycosis (Tinea Unguium)
      • Assessment by Mechanism of Action
        • Table Figure 7: Number of Products by Mechanism of Actions, Onychomycosis (Tinea Unguium)
        • Table Figure 8: Number of Products by Stage and Mechanism of Actions, Onychomycosis (Tinea Unguium)
        • Table Number of Products by Stage and Mechanism of Action, Onychomycosis (Tinea Unguium)
      • Assessment by Route of Administration
        • Table Figure 9: Number of Products by Routes of Administration, Onychomycosis (Tinea Unguium)
        • Table Figure 10: Number of Products by Stage and Routes of Administration, Onychomycosis (Tinea Unguium)
        • Table Number of Products by Stage and Route of Administration, Onychomycosis (Tinea Unguium)
      • Assessment by Molecule Type
        • Table Figure 11: Number of Products by Molecule Types, Onychomycosis (Tinea Unguium)
        • Table Figure 12: Number of Products by Stage and Molecule Types, Onychomycosis (Tinea Unguium)
        • Table Number of Products by Stage and Molecule Type, Onychomycosis (Tinea Unguium)
    • Tinea pedis (Athlete Foot)
      • Assessment by Target
        • Table Figure 13: Number of Products by Targets, Tinea pedis (Athlete Foot)
        • Table Figure 14: Number of Products by Stage and Targets, Tinea pedis (Athlete Foot)
        • Table Number of Products by Stage and Target, Tinea pedis (Athlete Foot)
      • Assessment by Mechanism of Action
        • Table Figure 15: Number of Products by Mechanism of Actions, Tinea pedis (Athlete Foot)
        • Table Figure 16: Number of Products by Stage and Mechanism of Actions, Tinea pedis (Athlete Foot)
        • Table Number of Products by Stage and Mechanism of Action, Tinea pedis (Athlete Foot)
      • Assessment by Route of Administration
        • Table Figure 17: Number of Products by Routes of Administration, Tinea pedis (Athlete Foot)
        • Table Figure 18: Number of Products by Stage and Routes of Administration, Tinea pedis (Athlete Foot)
        • Table Number of Products by Stage and Route of Administration, Tinea pedis (Athlete Foot)
      • Assessment by Molecule Type
        • Table Figure 19: Number of Products by Stage and Molecule Types, Tinea pedis (Athlete Foot)
        • Table Number of Products by Stage and Molecule Type, Tinea pedis (Athlete Foot)
  • Companies Involved in Therapeutics Development
    • Onychomycosis (Tinea Unguium)
      • Almirall SA
        • Table Onychomycosis (Tinea Unguium) –Pipeline by Almirall SA
      • Blueberry Therapeutics Ltd
        • Table Onychomycosis (Tinea Unguium) –Pipeline by Blueberry Therapeutics Ltd
      • Dermala Inc
        • Table Onychomycosis (Tinea Unguium) –Pipeline by Dermala Inc
      • Eisai Co Ltd
        • Table Onychomycosis (Tinea Unguium) –Pipeline by Eisai Co Ltd
      • Helix BioMedix Inc
        • Table Onychomycosis (Tinea Unguium) –Pipeline by Helix BioMedix Inc
      • Hexima Ltd
        • Table Onychomycosis (Tinea Unguium) –Pipeline by Hexima Ltd
      • Kaken Pharmaceutical Co Ltd
        • Table Onychomycosis (Tinea Unguium) –Pipeline by Kaken Pharmaceutical Co Ltd
      • Meiji Seika Pharma Co Ltd
        • Table Onychomycosis (Tinea Unguium) –Pipeline by Meiji Seika Pharma Co Ltd
      • Moberg Pharma AB
        • Table Onychomycosis (Tinea Unguium) –Pipeline by Moberg Pharma AB
      • NAL Pharmaceuticals Ltd
        • Table Onychomycosis (Tinea Unguium) –Pipeline by NAL Pharmaceuticals Ltd
      • Novabiotics Ltd
        • Table Onychomycosis (Tinea Unguium) –Pipeline by Novabiotics Ltd
      • Novan Inc
        • Table Onychomycosis (Tinea Unguium) –Pipeline by Novan Inc
      • Viamet Pharmaceuticals Inc
        • Table Onychomycosis (Tinea Unguium) –Pipeline by Viamet Pharmaceuticals Inc
    • Tinea pedis (Athlete Foot)
      • Astellas Pharma Inc
        • Table Tinea pedis (Athlete Foot) –Pipeline by Astellas Pharma Inc
      • Biolab Farmaceutica Ltda
        • Table Tinea pedis (Athlete Foot) –Pipeline by Biolab Farmaceutica Ltda
      • Blueberry Therapeutics Ltd
        • Table Tinea pedis (Athlete Foot) –Pipeline by Blueberry Therapeutics Ltd
      • Broda Tech LLC
        • Table Tinea pedis (Athlete Foot) –Pipeline by Broda Tech LLC
      • Novan Inc
        • Table Tinea pedis (Athlete Foot) –Pipeline by Novan Inc
      • Novoteris LLC
        • Table Tinea pedis (Athlete Foot) –Pipeline by Novoteris LLC
      • Sanotize Research And Development Corp
        • Table Tinea pedis (Athlete Foot) –Pipeline by Sanotize Research And Development Corp
      • Viamet Pharmaceuticals Inc
        • Table Tinea pedis (Athlete Foot) –Pipeline by Viamet Pharmaceuticals Inc
  • Dormant Projects
    • Onychomycosis (Tinea Unguium)
      • Table Onychomycosis (Tinea Unguium) –Dormant Projects
    • Tinea pedis (Athlete Foot)
      • Table Tinea pedis (Athlete Foot) –Dormant Projects
  • Discontinued Products
    • Onychomycosis (Tinea Unguium)
      • Table Onychomycosis (Tinea Unguium) –Discontinued Products
  • Product Development Milestones
    • Onychomycosis (Tinea Unguium)
      • Featured News & Press Releases
    • Tinea pedis (Athlete Foot)
      • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report